12:00 AM
 | 
Feb 17, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BA058-transdermal: Phase II data

Top-line data from a double-blind, international Phase II trial in 250 postmenopausal women with osteoporosis showed that once-daily 50, 100 and 150 µg doses of transdermal abaloparatide applied to the skin and removed after 5 minutes each met the primary endpoint of increasing BMD at lumbar spine from baseline to 6 months vs. placebo. Radius said high-dose transdermal abaloparatide led to the greatest increase in lumbar spine BMD with a 2.95% increase...

Read the full 339 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >